Regulatory approval

Published by the Health Service Executive. Approved

HER2 positive early breast cancer (EBC) following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with PACLitaxel or DOCEtaxel.

This is written in the approval document.

Reimbursement

Hospital

Citation

Trastuzumab Subcutaneous 21 days - Early Breast Cancer, 2021, version number 4, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6700/285_v4_Trastuzumab_SC_21days_EBC.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations Biomarkers Cancer types Therapies
HSE (1) HER2-positive Invasive Breast Carcinoma Docetaxel, Trastuzumab
HSE (1) ERBB2 amplification Invasive Breast Carcinoma Docetaxel, Trastuzumab
HSE (1) HER2-positive Invasive Breast Carcinoma Paclitaxel, Trastuzumab
HSE (1) ERBB2 amplification Invasive Breast Carcinoma Paclitaxel, Trastuzumab